These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. O'Mahony C; Tome-Esteban M; Lambiase PD; Pantazis A; Dickie S; McKenna WJ; Elliott PM Heart; 2013 Apr; 99(8):534-41. PubMed ID: 23339826 [TBL] [Abstract][Full Text] [Related]
3. The T-peak-to-T-end interval: a novel ECG marker for ventricular arrhythmia and appropriate ICD therapy in patients with hypertrophic cardiomyopathy. Dinshaw L; Münch J; Dickow J; Lezius S; Willems S; Hoffmann BA; Patten M Clin Res Cardiol; 2018 Feb; 107(2):130-137. PubMed ID: 28965260 [TBL] [Abstract][Full Text] [Related]
4. Improvement in sudden cardiac death risk prediction by the enhanced American College of Cardiology/American Heart Association strategy in Chinese patients with hypertrophic cardiomyopathy. Liu J; Wu G; Zhang C; Ruan J; Wang D; Zhang M; Wang L; Yang Y; Li X; Wang Y; Hui R; Zou Y; Kang L; Wang J; Song L Heart Rhythm; 2020 Oct; 17(10):1658-1663. PubMed ID: 32311532 [TBL] [Abstract][Full Text] [Related]
5. Management and outcomes of hypertrophic cardiomyopathy in young adults. Baron É; Karam N; Donal E; Puscas T; Mirabel M; Bacher A; Wahbi K; Mazzella JM; Jeunemaitre X; Reant P; Hagège A; Arch Cardiovasc Dis; 2021; 114(6-7):465-473. PubMed ID: 33744178 [TBL] [Abstract][Full Text] [Related]
6. Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy: What has Changed in The Guidelines? Reis L; Teixeira R; Fernandes A; Almeida I; Madeira M; Silva J; Botelho A; Pais J; Nascimento J; Gonçalves L Arq Bras Cardiol; 2018 Jun; 110(6):524-531. PubMed ID: 30226910 [TBL] [Abstract][Full Text] [Related]
7. A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy. Norrish G; Ding T; Field E; McLeod K; Ilina M; Stuart G; Bhole V; Uzun O; Brown E; Daubeney PEF; Lota A; Linter K; Mathur S; Bharucha T; Kok KL; Adwani S; Jones CB; Reinhardt Z; Omar RZ; Kaski JP Europace; 2019 Oct; 21(10):1559-1565. PubMed ID: 31155643 [TBL] [Abstract][Full Text] [Related]
8. Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation. Liebregts M; Faber L; Jensen MK; Vriesendorp PA; Hansen PR; Seggewiss H; Horstkotte D; Adlova R; Michels M; Bundgaard H; Ten Berg JM; Veselka J Europace; 2018 Sep; 20(FI2):f198-f203. PubMed ID: 29016960 [TBL] [Abstract][Full Text] [Related]
9. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death. Freitas P; Ferreira AM; Arteaga-Fernández E; de Oliveira Antunes M; Mesquita J; Abecasis J; Marques H; Saraiva C; Matos DN; Rodrigues R; Cardim N; Mady C; Rochitte CE J Cardiovasc Magn Reson; 2019 Aug; 21(1):50. PubMed ID: 31412875 [TBL] [Abstract][Full Text] [Related]
10. Validation of the new American College of Cardiology/American Heart Association Guidelines for the risk stratification of sudden cardiac death in a large Mediterranean cohort with Hypertrophic Cardiomyopathy. Zegkos T; Tziomalos G; Parcharidou D; Ntelios D; Papanastasiou CA; Karagiannidis E; Gossios T; Rouskas P; Katranas S; Paraskevaidis S; Karvounis H; Efthimiadis G Hellenic J Cardiol; 2022; 63():15-21. PubMed ID: 34147674 [TBL] [Abstract][Full Text] [Related]
11. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Vriesendorp PA; Schinkel AF; Liebregts M; Theuns DA; van Cleemput J; Ten Cate FJ; Willems R; Michels M Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):829-35. PubMed ID: 25922410 [TBL] [Abstract][Full Text] [Related]
12. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy. Maron MS; Rowin EJ; Wessler BS; Mooney PJ; Fatima A; Patel P; Koethe BC; Romashko M; Link MS; Maron BJ JAMA Cardiol; 2019 Jul; 4(7):644-657. PubMed ID: 31116360 [TBL] [Abstract][Full Text] [Related]
13. [Feasibility of the 2014 European guidelines risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy in Chinese patients]. Zhu SH; Li Y; Huang W; Jiang H; Li SN; Chen L; Huang S; Yu HS; Xu B Zhonghua Xin Xue Guan Bing Za Zhi; 2017 May; 45(5):404-408. PubMed ID: 28511325 [No Abstract] [Full Text] [Related]
14. Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy. Maron BJ; Casey SA; Chan RH; Garberich RF; Rowin EJ; Maron MS Am J Cardiol; 2015 Sep; 116(5):757-64. PubMed ID: 26183790 [TBL] [Abstract][Full Text] [Related]
15. Implantable cardioverter defibrillator therapy and sudden death risk stratification in hypertrophic cardiomyopathy patients with midventricular obstruction: A single-center experience. Maeda R; Minami Y; Haruki S; Kanbayashi K; Itani R; Suzuki A; Ejima K; Shiga T; Shoda M; Hagiwara N Int J Cardiol; 2016 Jul; 214():419-22. PubMed ID: 27088403 [TBL] [Abstract][Full Text] [Related]
16. Predicting therapies in Japanese hypertrophic cardiomyopathy patients with an implantable cardioverter-defibrillator using the 2014 European Society of Cardiology guidelines. Nakano M; Kondo Y; Nakano M; Kajiyama T; Miyazawa K; Hayashi T; Ito R; Takahira H; Kobayashi Y Heart Vessels; 2021 Jan; 36(1):99-104. PubMed ID: 32666207 [TBL] [Abstract][Full Text] [Related]
17. Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study. Rowin EJ; Maron MS; Adler A; Albano AJ; Varnava AM; Spears D; Marsy D; Heitner SB; Cohen E; Leong KMW; Winters SL; Martinez MW; Koethe BC; Rakowski H; Maron BJ Heart Rhythm; 2022 May; 19(5):782-789. PubMed ID: 34933112 [TBL] [Abstract][Full Text] [Related]
18. Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy. Magrì D; Limongelli G; Re F; Agostoni P; Zachara E; Correale M; Mastromarino V; Santolamazza C; Casenghi M; Pacileo G; Valente F; Musumeci B; Maruotti A; Volpe M; Autore C Heart; 2016 Apr; 102(8):602-9. PubMed ID: 26849900 [TBL] [Abstract][Full Text] [Related]
19. Implantable cardioverter defibrillators in patients with electrical heart disease and hypertrophic cardiomyopathy: data from the German device registry. Frommeyer G; Reinke F; Andresen D; Kleemann T; Spitzer SG; Jehle J; Brachmann J; Stellbrink C; Hochadel M; Senges J; Eckardt L Clin Res Cardiol; 2020 Apr; 109(4):508-512. PubMed ID: 31367999 [TBL] [Abstract][Full Text] [Related]
20. QT spatial dispersion and sudden cardiac death in hypertrophic cardiomyopathy: Time for reappraisal. Magrì D; Santolamazza C; Limite L; Mastromarino V; Casenghi M; Orlando P; Pagannone E; Musumeci MB; Maruotti A; Ricotta A; Oliviero G; Piccirillo G; Volpe M; Autore C J Cardiol; 2017 Oct; 70(4):310-315. PubMed ID: 28341542 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]